Fifth disease that Dupixent has demonstrated positive pivotal results.... Jul 29
As discussed during our Capital Markets Day in February, simplifying the CHC product portfolio is an important part of our strategy to focus our resources ... Jul 14
Trial will evaluate potential of next generation of influenza vaccines with combined mRNA technology and flu vaccine development expertise... Jun 22
The approval confirms Aubagio as the first oral multiple sclerosis (MS) therapy for first-line treatment of children and adolescents with MS in the European ... Jun 19
... Jun 11
KY1005 binds to OX40-Ligand and has the potential to treat a wide variety of immune-mediated diseases and inflammatory disorders.... Jan 13
Sanofi and Kymab, a clinical-stage biopharmaceutical company developing fully human monoclonal antibodies with a focus on immune-mediated diseases and immuno-oncology therapeutics... Jan 11
Sanofi renewed a partnership agreement with the WHO, consolidating a 20-year collaboration to fight some of the most Neglected Tropical Diseases... Dec 15
Atopic dermatitis is a chronic inflammatory disease of the skin that can be debilitating, and severe disease can significantly impact many aspects of life for ... Nov 30
The EC has approved MenQuadfi for active immunization against invasive meningococcal disease caused by Neisseria meningitidis serogroups A, C, W and Y.... Nov 23
These data reinforce the well-established long-term safety profile of Dupixent in moderate-to-severe atopic dermatitis.... Oct 29
New late-breaking data showing additional improvements in disease severity and extent at the microscopic level ... Oct 26
Dupixent combined with TCS in children aged 6 to 11 years with severe atopic dermatitis that is uncontrolled on topical prescription therapies... Oct 16
Sanofi and Translate Bio today announced the preclinical results of an mRNA-based vaccine candidate against SARS-CoV-2... Oct 15
A pivotal Phase 3 trial of Dupixent met its primary and all key secondary endpoints in children aged 6 to 11 years with uncontrolled moderate-... Oct 13
Avalglucosidase alfa is an investigational enzyme replacement therapy, which, if approved, would offer a potential new standard of care for patients with Pompe disease... Oct 02
Sanofi announced today the successful completion of its acquisition of Principia Biopharma Inc. for $100 per share in cash.... Sep 28
CHMP has adopted a positive opinion for Supemtek for active immunization for the prevention of influenza in adults... Sep 23
Sanofi and GSK finalised and signed today an advanced purchase agreement with the European Commission (EC) for supplying their vaccine... Sep 20
-Advertisements-
Wednesday, May 15, 2024
.jpeg)
